Wedbush Reaffirms “Outperform” Rating for Artiva Biotherapeutics (NASDAQ:ARTV)

Artiva Biotherapeutics (NASDAQ:ARTV)‘s stock had its “outperform” rating reaffirmed by equities researchers at Wedbush in a note issued to investors on Tuesday,Benzinga reports. They currently have a $18.00 price objective on the stock. Wedbush’s target price would indicate a potential upside of 394.51% from the company’s previous close.

A number of other research analysts also recently issued reports on the company. HC Wainwright assumed coverage on Artiva Biotherapeutics in a research note on Monday, December 30th. They set a “buy” rating and a $20.00 price objective for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price target on shares of Artiva Biotherapeutics in a report on Tuesday. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $20.40.

Artiva Biotherapeutics Trading Down 8.8 %

NASDAQ ARTV opened at $3.64 on Tuesday. The business’s fifty day moving average is $4.84 and its 200 day moving average is $9.33. Artiva Biotherapeutics has a fifty-two week low of $3.37 and a fifty-two week high of $17.31.

Institutional Trading of Artiva Biotherapeutics

Several institutional investors have recently made changes to their positions in ARTV. BNP Paribas Financial Markets bought a new position in shares of Artiva Biotherapeutics during the third quarter worth $42,000. Charles Schwab Investment Management Inc. lifted its stake in Artiva Biotherapeutics by 8.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 43,526 shares of the company’s stock worth $439,000 after purchasing an additional 3,233 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Artiva Biotherapeutics by 64.0% during the 4th quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock valued at $87,000 after purchasing an additional 3,361 shares during the last quarter. Northern Trust Corp grew its position in shares of Artiva Biotherapeutics by 3.8% during the fourth quarter. Northern Trust Corp now owns 117,112 shares of the company’s stock valued at $1,180,000 after purchasing an additional 4,335 shares in the last quarter. Finally, Barclays PLC increased its holdings in shares of Artiva Biotherapeutics by 23.2% in the fourth quarter. Barclays PLC now owns 24,161 shares of the company’s stock worth $244,000 after purchasing an additional 4,545 shares during the last quarter.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.